
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis is a promising biopharmaceutical firm with a strong focus on cancer treatments. The company's pipeline includes multiple potential blockbuster drugs, and its upcoming catalysts, such as the initiation of Phase 3 trials for zanzalintinib and topline results from its Phase 3 study of zanzalintinib in combination with Opdivo, have the potential to significantly boost the company's valuation. Additionally, the company's strong cash flow and share repurchase program provide additional support for its stock. However, investors should be aware of the inherent risks associated with drug development and the competitive landscape of the industry, as well as the potential for dilution through future equity offerings.
Bears say
Exelixis is facing potential challenges with their current commercial portfolio as Cabometyx approaches its patent expiry in 2031 and their pipeline drug zanzalintinib displays comparable efficacy, but lacks meaningful statistical significance in certain subsets. Additionally, their early-stage ADC platform is still in the early stages of development and may not provide meaningful returns in the near future. With only two weeks of data missing, it appears Exelixis' stock may have reached its peak and could see a decline in the near term.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares